Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study (vol 8, pg e185, 2021)

被引：0
|
作者：
Orkin, C.
Oka, S.
Philibert, P.
机构：
来源：
LANCET HIV | 2021年 / 8卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：E734 / E734
页数：1
相关论文
共 50 条
  • [1] Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
    Orkin, Chloe
    Oka, Shinichi
    Philibert, Patrick
    Brinson, Cynthia
    Bassa, Ayesha
    Gusev, Denis
    Degen, Olaf
    Garcia, Juan Gonzalez
    Morell, Enrique Bernal
    Tan, Darrell H. S.
    D'Amico, Ronald
    Dorey, David
    Griffith, Sandy
    Thiagarajah, Shanker
    St Clair, Marty
    Van Solingen-Ristea, Rodica
    Crauwels, Herta
    Ford, Susan L.
    Patel, Parul
    Chounta, Vasiliki
    Vanveggel, Simon
    Cutrell, Amy
    Van Eygen, Veerle
    Vandermeulen, Kati
    Margolis, David A.
    Smith, Kimberly Y.
    Spreen, William R.
    [J]. LANCET HIV, 2021, 8 (04): : e185 - e196
  • [2] Long-acting cabotegravir plus rilpivirine for HIV treatment: FLAIR week 96 results
    Orkin, C.
    Oka, S.
    Philibert, P.
    Brinson, C.
    Bassa, A. C.
    Gusev, D.
    Degen, O.
    Gonzalez Garcia, J.
    D'Amico, R.
    Dorey, D.
    Griffith, S.
    Margolis, D. A.
    St Clair, M.
    Williams, P.
    Spreen, W. R.
    [J]. HIV MEDICINE, 2020, 21 : 14 - 14
  • [3] Week 124 results of the randomized, open-label, Phase 3 FLAIR study evaluating long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection (ITT-E population)
    Orkin, C.
    D'Amico, R.
    Bernal Morell, E.
    Tan, D. H. S.
    Katner, H.
    Singh, Y.
    Stellbrink, H-J
    Belonosova, E.
    DeMoor, R.
    Griffith, S.
    Thiagarajah, S.
    Van Solingen-Ristea, R.
    Ford, S. L.
    Crauwels, H.
    Patel, P.
    Cutrell, A.
    Smith, K. Y.
    Vandermeulen, K.
    St Clair, M.
    Spreen, W. R.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 : 22 - 22
  • [4] Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study
    Orkin, Chloe
    Morell, Enrique Bernal
    Tan, Darrell H. S.
    Katner, Harold
    Stellbrink, Hans-Juergen
    Belonosova, Elena
    DeMoor, Rebecca
    Griffith, Sandy
    Thiagarajah, Shanker
    Van Solingen-Ristea, Rodica
    Ford, Susan L.
    Crauwels, Herta
    Patel, Parul
    Cutrell, Amy
    Smith, Kimberly Y.
    Vandermeulen, Kati
    Birmingham, Eileen
    St Clair, Marty
    Spreen, William R.
    D'Amico, Ronald
    [J]. LANCET HIV, 2021, 8 (11): : E668 - E678
  • [5] Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
    Margolis, David A.
    Gonzalez-Garcia, Juan
    Stellbrink, Hans-Juergen
    Eron, Joseph J.
    Yazdanpanah, Yazdan
    Podzamczer, Daniel
    Lutz, Thomas
    Angel, Jonathan B.
    Richmond, Gary J.
    Clotet, Bonaventura
    Gutierrez, Felix
    Sloan, Louis
    St Clair, Marty
    Murray, Miranda
    Ford, Susan L.
    Mrus, Joseph
    Patel, Parul
    Crauwels, Herta
    Griffith, Sandy K.
    Sutton, Kenneth C.
    Dorey, David
    Smith, Kimberly Y.
    Williams, Peter E.
    Spreen, William R.
    [J]. LANCET, 2017, 390 (10101): : 1499 - 1510
  • [6] Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
    Swindells, Susan
    Lutz, Thomas
    Van Zyl, Lelanie
    Porteiro, Norma
    Stoll, Matthias
    Mitha, Essack
    Shon, Alyssa
    Benn, Paul
    Huang, Jenny O.
    Harrington, Conn M.
    Hove, Kai
    Ford, Susan L.
    Talarico, Christine L.
    Chounta, Vasiliki
    Crauwels, Herta
    Van Solingen-Ristea, Rodica
    Vanveggel, Simon
    Margolis, David A.
    Smith, Kimberly Y.
    Vandermeulen, Kati
    Spreen, William R.
    [J]. AIDS, 2022, 36 (02) : 185 - 194
  • [7] Cabotegravir plus rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS Week 96 results
    Swindells, S.
    Lutz, T.
    Van Zyl, L.
    Porteiro, N.
    Benn, P.
    Huang, J.
    Harrington, C.
    Hove, K.
    Ford, S.
    Talarico, C.
    Chounta, V.
    Crauwels, H.
    Van Solingen-Ristea, R.
    Vanveggel, S.
    Margolis, D.
    Smith, K.
    Vandermeulen, K.
    Spreen, W.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 19 - 21
  • [8] Cabotegravir plus rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS week 96 results
    Swindells, Susan
    Lutz, Thomas
    Van Zyl, Lelanie
    Porteiro, Norma
    Benn, Paul
    Huang, Jenny O.
    Harrington, Conn M.
    Hove, Kai
    Ford, Susan L.
    Talarico, Christine L.
    Chounta, Vasiliki
    Crauwels, Herta
    Van Solingen-Ristea, Rodica
    Vanveggel, Simon
    Margolis, David A.
    Smith, Kimberly Y.
    Vandermeulen, Kati
    Spreen, William R.
    Baum, Alexander
    [J]. INFECTION, 2021, 49 (SUPPL 1) : S7 - S8
  • [9] Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
    Jaeger, Hans
    Overton, Edgar
    Richmond, Gary
    Rizzardini, Giuliano
    Andrade-Villanueva, Jaime Federico
    Mngqibisa, Rosie
    Hermida, Antonio Ocampo
    Thalme, Anders
    Belonosova, Elena
    Ajana, Faiza
    Benn, Paul D.
    Wang, Yuanyuan
    Hudson, Krischan J.
    Espanol, Carlos Martin
    Ford, Susan L.
    Crauwels, Herta
    Margolis, David A.
    Talarico, Christine L.
    Smith, Kimberly Y.
    van Eygen, Veerle
    Van Solingen-Ristea, Rodica
    Vanveggel, Simon
    Spreen, William R.
    [J]. LANCET HIV, 2021, 8 (11): : E679 - E689
  • [10] Patient-reported tolerability and acceptability of cabotegravir plus rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study
    Murray, Miranda
    Pulido, Federico
    Mills, Anthony
    Ramgopal, Moti
    LeBlanc, Roger
    Jaeger, Hans
    Canon, Viviam
    Dorey, David
    Griffith, Sandy
    Mrus, Joseph
    Spreen, William
    Margolis, David
    [J]. HIV RESEARCH & CLINICAL PRACTICE, 2019, 20 (4-5) : 111 - 122
12345